Blockchain Registration Transaction Record

Soligenix Reports Q3 Progress, Key Milestones for Rare Disease Treatments

Soligenix reports Q3 2025 results with key milestones for HyBryte™ in CTCL and SGX302 in psoriasis. Company maintains strong cash position and advances rare disease treatments.

This development matters because Soligenix is advancing treatments for rare diseases that currently lack effective therapeutic options. The progress in HyBryte™ for cutaneous T-cell lymphoma represents a potential breakthrough for patients suffering from this rare cancer who have limited treatment alternatives. The expansion into psoriasis treatment with SGX302 could benefit millions of patients worldwide who struggle with this chronic inflammatory condition. Additionally, the company's vaccine development programs address critical public health threats including ricin exposure, filoviruses like Ebola and Marburg, and COVID-19 variants. For investors, Soligenix's strong cash position and extended operational runway through 2026 provide stability while the company advances multiple late-stage clinical programs that could deliver significant value if approved.